Immunome, Inc. (NASDAQ:IMNM) Short Interest Down 13.9% in January

Immunome, Inc. (NASDAQ:IMNM) saw a large decline in short interest during the month of January. As of January 31st, there was short interest totalling 9,070,000 shares, a decline of 13.9% from the January 15th total of 10,540,000 shares. Based on an average trading volume of 1,000,000 shares, the short-interest ratio is presently 9.1 days. Approximately 13.0% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on IMNM shares. Piper Sandler decreased their target price on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a research report on Thursday, November 14th. Wedbush reissued an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research note on Monday, January 13th. Finally, Stephens initiated coverage on Immunome in a report on Friday, November 8th. They set an “overweight” rating and a $30.00 target price for the company. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Immunome has an average rating of “Buy” and an average price target of $28.60.

Insider Transactions at Immunome

In other news, insider Robert Lechleider acquired 15,805 shares of the firm’s stock in a transaction that occurred on Thursday, November 21st. The shares were bought at an average cost of $9.48 per share, with a total value of $149,831.40. Following the acquisition, the insider now owns 15,805 shares in the company, valued at approximately $149,831.40. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Clay B. Siegall bought 150,000 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was purchased at an average price of $7.75 per share, with a total value of $1,162,500.00. Following the transaction, the chief executive officer now directly owns 669,636 shares in the company, valued at $5,189,679. The trade was a 28.87 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 252,862 shares of company stock valued at $2,140,545. Insiders own 8.60% of the company’s stock.

Institutional Investors Weigh In On Immunome

Large investors have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. raised its holdings in shares of Immunome by 217.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company’s stock valued at $6,469,000 after acquiring an additional 302,916 shares in the last quarter. Victory Capital Management Inc. raised its holdings in Immunome by 48.1% in the 3rd quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock worth $10,684,000 after purchasing an additional 237,497 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Immunome by 13.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company’s stock worth $17,657,000 after purchasing an additional 144,557 shares during the period. Magnus Financial Group LLC boosted its stake in shares of Immunome by 107.8% during the 4th quarter. Magnus Financial Group LLC now owns 53,536 shares of the company’s stock valued at $569,000 after purchasing an additional 27,777 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its position in shares of Immunome by 22.2% during the third quarter. Point72 Asset Management L.P. now owns 470,647 shares of the company’s stock valued at $6,881,000 after buying an additional 85,580 shares during the period. 44.58% of the stock is currently owned by institutional investors.

Immunome Trading Down 0.3 %

Immunome stock opened at $10.40 on Tuesday. Immunome has a 1-year low of $8.97 and a 1-year high of $30.96. The firm has a 50-day moving average of $10.83 and a 200-day moving average of $12.38.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.